NCT00611767View on ClinicalTrials.gov

GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Alcoholism
Interventions
DRUG

Thiopental

A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).

DRUG

Placebo

A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).

Trial Locations (1)

06516

VA Connecticut Healthcare System, West Haven

All Listed Sponsors
collaborator

VA Connecticut Healthcare System

FED

lead

Yale University

OTHER

NCT00611767 - GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence | Biotech Hunter | Biotech Hunter